DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer.
Defective DNA mismatch repair (MMR) occurs in approximately 15% of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.
Sinicrope
Frank A
FA
Division of Oncology, Mayo Clinic and Mayo Cancer Center, Rochester, MN 55905, USA. sinicrope.frank@mayo.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D053843:DNA Mismatch Repair; D006801:Humans; D016896:Treatment Outcome
D000970:Antineoplastic Agents